Clinical trials: Insulin
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of the trial is to compare the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus.
- Trial name
- DUAL™ V (NCT01952145)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 91 sites in United States, Argentina and 8 more
- Volunteers
- 557 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus
The purpose of this study is: To assess the efficacy of Nasulin vs. placebo as indicated by time spent in euglycemia, assessed by continuous glucose monitoring data and serum fructosamine levels in patient volunteers with Type 2…
- Trial name
- CPEX-011 (NCT00850096)
- Testing
- Nasulin
- Where
- 21 sites in United States
- Volunteers
- 94 people
- Sponsor
- CPEX Pharmaceuticals Inc.
Schizophrenia, Schizoaffective Disorder
Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine
Atypical antipsychotic medications, such as olanzapine, cause metabolic side effects, including weight gain, extra fat around the middle of the body, high blood sugar, and high cholesterol.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Obesity
- Trial name
- NCT00512070
- Testing
- olanzapine and melatonin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Type 2 Diabetes
Impact of Breakfast Composition on Glycemic and Incretin Responses in Individuals With Type 2 Diabetes
This study examined the effect of a high protein or high carbohydrate breakfast on the glucose and insulin response following the breakfast meal, as well as the subsequent response following the lunch meal.
- Trial name
- NCT02180646
- Testing
- High protein breakfast, High carb breakfast
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Type 2 Diabetes
Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake
27 Type 2 diabetic subjects (HbA1c 7.5 - 9.5%) currently treated with diet and exercise alone or with oral antidiabetic agents will be randomly assigned to one of three treatment groups: insulin detemir, liraglutide, or…
- Trial name
- NCT01232946
- Testing
- liraglutide, insulin detemir, liraglutide plus insulin detemir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
Diabetes Mellitus, Non-Insulin-Dependent
Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)
A clinical study determines the safety and efficacy of sitagliptin (MK0431) in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy
- Trial name
- NCT00758069
- Testing
- sitagliptin phosphate, Comparator: Sitagliptin
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy
The WINGMEN trial aims to understand how a hormone-like protein called insulin-like growth factor (IGF) helps prostate cancers grow and become aggressive.
- Trial name
- WINGMEN (NCT05110495)
- Testing
- Xentuzumab
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- University of Oxford
Myotonic Dystrophy
Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)
The aim of this study is to investigate the safety and feasibility of daily subcutaneous injections of recombinant IGF1 complexed with IGF binding protein 3 (SomatoKine-INSMED) as a treatment for muscle wasting and weakness in…
- Trial name
- NCT00233519
- Testing
- SomatoKine/IPLEX
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Diabetes Mellitus, Type 1
Assessing Effectiveness of a Diabetes Navigator in Increasing Progression of Advanced Diabetes Technologies
The goal of this randomized control trial is to determine if the support of a Diabetes Navigator is more effective than standard care in improving uptake and use of advanced diabetes technology among patients with type 1 diabetes.
- Trial name
- IMPACT-T1D (NCT06229236)
- Testing
- Diabetes Navigator
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Johns Hopkins University
Diabetes
Point-of-Care Glucose Testing and Insulin Supplementation
Capillary point-of-care (POC) testing is advocated as a valuable aid in the management of diabetes and hyperglycemia in the hospital setting.
- Trial name
- POC (NCT01702311)
- Testing
- Bedtime insulin Aspart (Novolog)
- Where
- 2 sites in United States
- Volunteers
- 235 people
- Sponsor
- Emory University
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
Three Approaches to Glucose Monitoring in Non-insulin Treated Diabetes
For the nearly 75% of patients living with type 2 diabetes (T2DM) that do not use insulin, decisions regarding self-monitoring of blood glucose (SMBG) are unclear.
- Trial name
- NCT02033499
- Testing
- SMBG
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- University of North Carolina, Chapel Hill
Insulin Sensitivity, Obstructive Sleep Apnea
Obesity, Sleep Apnea, and Insulin Resistance
Obstructive sleep apnea (OSA) and type 2 diabetes confer increasing economic, social, and public health burdens in the United States.
- Trial name
- NCT02192684
- Testing
- Pioglitazone
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Stanford University
Hypercholesterolaemia
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Primary Objectives: To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with…
- Trial name
- NCT02585778
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Where
- 110 sites in United States, Austria and 8 more
- Volunteers
- 517 people
- Sponsor
- Sanofi
Insulin-Like Growth Factor-1 Deficiency, Growth Disorders
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
This study is intended to assess the effects of once daily dosing of recombinant human insulin-like growth factor (rhIGF-1) in increasing height velocity.
- Trial name
- NCT00125190
- Testing
- rhIGF-1 (mecasermin) for a period of 86 weeks
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Metabolic Syndrome
A Short Term Evaluation of a Structured Weight Loss Plan in Overweight and Obese Adults
The present study is designed to examine the effect of changes in body weight and related parameters associated with a commercially-available, low-carbohydrate diet plan.
- Trial name
- NCT02774668
- Testing
- "Grab-and-Go" meal plan, "Jump-Start" meal plan
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Type 2 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Primary Objective: To compare the efficacy of insulin glargine new formulation and Lantus in terms of change in HbA1c from baseline to endpoint (scheduled month 6) in adult participants with type 2 diabetes mellitus Secondary…
- Trial name
- EDITION I (NCT01499082)
- Testing
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Where
- 193 sites in United States, Canada and 11 more
- Volunteers
- 807 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System
The purpose of this study is to assess the efficacy of the Low Glucose Suspend (LGS) feature in reducing hypoglycemia with the MiniMed Paradigm® X54 System with hypoglycemic induction from exercise.
- Trial name
- NCT01148862
- Testing
- The MiniMed Paradigm® X54 System
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Medtronic MiniMed, Inc.
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
The primary aim of the study is to determine the impact on hepatic steatosis of replacing premeal rapid-acting insulin for exenatide (Byetta) while maintaining bedtime long-acting detemir (Levemir) insulin in well-controlled…
- Trial name
- NCT01006889
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Hypertension
Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension
The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) compared to aliskiren monotherapy when given to metabolic syndrome patients with…
- Trial name
- AIMS (NCT00797316)
- Testing
- Aliskiren, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 532 people
- Sponsor
- Novartis
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
Examine the effects of TI in combination with an anti-diabetic regimen including inhaled insulin versus anti-diabetic treatment without inhaled insulin on lung function \& pulmonary safety
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Moderate Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT00642616
- Testing
- Technosphere® Insulin, Usual Care
- Where
- 21 sites in United States, Russia and 1 more
- Volunteers
- 34 people
- Sponsor
- Mannkind Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.